Funding to establish an adaptive clinical trial for glioma patients in the UK.
Purpose and scope
We are determined to see more people affected with brain tumours have access to and take part in clinical trials. To accomplish this aim, we have created this funding opportunity to promote the establishment of brain tumour trial infrastructure. This will facilitate an increase in the number of brain tumour clinical trials, permit more newly diagnosed people to enter trials, make the United Kingdom a more attractive place to open trials, and increase availability of banked brain tumour tissue for research.
Funding of up to £500,000 per year can be requested.
The funding should cover:
Part A costs as defined by AcoRD
Biobanking costs. Only directly incurred costs may be claimed, please see our finance guidelines
for more information.
Payment to collaborating centres on a per-patient basis for milestones such as recruitment and
submission of biobanking samples.
Buy-out of clinical time for a researcher to develop the additional study arms.
The award is open to applications from UK-based universities, NHS sites or other recognised UK
higher research institutions.
The trial must be co-ordinated by a lead Clinical Trials Unit (CTU). Experience of co-ordinating multi-centre brain
tumour trials and/or opening and running an
adaptive interventional study will be looked upon
favourably. The CTU must be willing to facilitate arms of the trial being opened and run by Clinical
Investigators from other centres.
Clinical investigators should have a contract of employment with the host institution that exceeds
the planned finish date of the research by at least 12 months.
A CTU may lead on only one application.
Applicants must consult The Brain Tumour Charity's Research Involvement Network (RIN)
during the development of the proposal and must plan for continued RIN input as the trial is run.
All applications must have input from those affected by brain tumours as early as possible, preferably during scoping of the project. We strongly recommend that applicants access our
Research Involvement Network (RIN) for public and patient involvement. In order to receive feedback from the RIN, please allow for a minimum of 3 weeks turnaround time.
The potential for the trial to facilitate increased testing of new therapeutics in the UK.
The ability of the trial to increase the percentage of newly diagnosed patients offered a clinical
trial and to increase patient access to novel therapeutics (including wide geographic spread across
The degree to which the trial will build capacity for more trials to be designed.
The quality and relevance of the “backbone" research question.
The ability of the trial to improve the availability and quality of molecular diagnosis.
The ability of the trial to improve access to high-quality well-characterised brain tumour tissue
for the wider research community.